Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05884814
Other study ID # RA HM-2023-009
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 1, 2023
Est. completion date December 31, 2024

Study information

Verified date July 2023
Source Dasman Diabetes Institute
Contact Ebaa AlOzairi, MBChB
Phone +965 22242999
Email ebaa.alozairi@dasmaninstitute.rog
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aims of the current study are 1. to compare the effects of acute morning and afternoon resistance exercise on blood glucose levels in people with type 1 diabetes. 2. to compare the effects of morning and afternoon resistance exercise training on cardiometabolic health outcomes in people with type 1 diabetes


Recruitment information / eligibility

Status Recruiting
Enrollment 54
Est. completion date December 31, 2024
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 21 Years to 60 Years
Eligibility Inclusion Criteria: - Physician confirmed type 1 diabetes for at least 1 year - Stable insulin therapy for 3 months prior to the study Exclusion Criteria: - BMI of 45 or higher - BP of 160/100mmHg or higher - autonomic neuropathy - severe proliferative retinopathy - joint or limb injuries preventing weight-bearing activity - autonomic neuropathy - severe proliferative retinopathy - any other medical condition that prevents participants from exercising safely.

Study Design


Intervention

Behavioral:
Morning exercise
Between 6-10am participants will attend the gym and perform 10 min of warm up exercise, 3 sets of 7 resistance exercises ( leg press, calf press, leg curl, chest press, lateral raise, seated row and plank)
Afternoon exercise
Between 4-8pm participants will attend the gym and perform 10 min of warm up exercise, 3 sets of 7 resistance exercises ( leg press, calf press, leg curl, chest press, lateral raise, seated row and plank)
Habitual physical activity levels
Participants will be asked to maintain their normal activity levels

Locations

Country Name City State
Kuwait Dasman Diabetes Institute Kuwait City

Sponsors (1)

Lead Sponsor Collaborator
Dasman Diabetes Institute

Country where clinical trial is conducted

Kuwait, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in muscle strength Sum of one repetition maximum for the 7 resistance exercise Change from baseline to 12 weeks
Primary Change in interstitial glucose time in range Interstitial glucose time in range (3.9-10mmol/L) measured via continuous glucose monitoring Change from 6 hours before (baseline) to 6 hours after (post-exercise) an exercise training session
Secondary Change in appendicular skeletal muscle mass Measured by DEXA Change from baseline to 12 weeks
Secondary Change in whole body fat mass Measured by DEXA Change from baseline to 12 weeks
Secondary Change in physical function Measured by the short performance physical battery Change from baseline to 12 weeks
Secondary Change in HbA1c HbA1c concentration Change from baseline to 12 weeks
Secondary Change in interstitial glucose average Interstitial average glucose measured via continuous glucose monitoring Change from 6 hours before (baseline) to 6 hours after (post-exercise) an exercise training session
Secondary Change in interstitial glucose variability Interstitial glucose variability measured via continuous glucose monitoring Change from 6 hours before (baseline) to 6 hours after (post-exercise) an exercise training session
Secondary Change in interstitial glucose time in hypoglycaemia Interstitial glucose time in range (<3.9mmol/L) measured via continuous glucose monitoring Change from 6 hours before (baseline) to 6 hours after (post-exercise) an exercise training session
Secondary Change in interstitial glucose time in hyperglycaemia Interstitial glucose time in range (>10mmol/L) measured via continuous glucose monitoring Change from 6 hours before (baseline) to 6 hours after (post-exercise) an exercise training session
See also
  Status Clinical Trial Phase
Recruiting NCT05653518 - Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes N/A
Enrolling by invitation NCT05515939 - Evaluating the InPen in Pediatric Type 1 Diabetes
Completed NCT05109520 - Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
Recruiting NCT04016987 - Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes N/A
Active, not recruiting NCT04190368 - Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes N/A
Recruiting NCT05413005 - Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus Early Phase 1
Active, not recruiting NCT04668612 - Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes N/A
Recruiting NCT05414409 - The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action Phase 2
Completed NCT02837094 - Enhanced Epidermal Antigen Specific Immunotherapy Trial -1 Phase 1
Recruiting NCT05670366 - The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes N/A
Active, not recruiting NCT05418699 - Real-life Data From Diabetic Patients on Closed-loop Pumps
Completed NCT04084171 - Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6 N/A
Recruiting NCT06144554 - Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
Recruiting NCT05379686 - Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes N/A
Recruiting NCT05153070 - Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes Phase 2
Recruiting NCT05281614 - Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D Early Phase 1
Withdrawn NCT04259775 - Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes N/A
Active, not recruiting NCT01600924 - Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
Completed NCT02897557 - Insulet Artificial Pancreas Early Feasibility Study N/A
Completed NCT02914886 - Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS) Phase 4